Chapter 8 174 22. Ison G, Beaver JA, McGuinn WD, et al. FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(18):4545-4549. doi:10.1158/10780432.CCR-16-0638 23. EMA. Public Assessment Report: Kolbam.; 2015. 24. EMA. Scientific Discussion: Orfadin.; 2005. 25. Eichler HG, Bloechl-Daum B, Bauer P, et al. “Threshold-crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials? Clin Pharmacol Ther. 2016;100(6):699-712. doi:10.1002/cpt.515 26. Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033-1039. doi:10.1002/pds.4297 27. DreyerNA.AdvancingaFrameworkforRegulatory Use of Real-World Evidence: When Real Is Reliable. Ther Innov Regul Sci. 2018;52(3):362368. doi:10.1177/2168479018763591 28. Brennan Z. Gilead and Novartis Seek to Expand What FDA Considers as Real-World Data and Real-World Evidence. Accessed August 12, 2019. https://www.raps.org/news-and-articles/newsarticles/2019/7/gilead-and-novartis-seek-toexpand-what-fda-consid 29. FAQ’s - Unmet Medical Need. Accessed August 12, 2019. https://www.fagg-afmps.be/sites/ default/files/content/faq_1.5_20190726.pdf 30. Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014. BMJ Open. 2016;6(6):e011666. doi:10.1136/ bmjopen-2016-011666 31. Mutual Recognition Agreement (MRA) - FDA. Accessed August 12, 2019. https://www.fda. gov/international-programs/internationalarrangements/mutual-recognition-agreementmra 32. Mutual recognition agreements (MRA) - EMA. Accessed August 12, 2019. https:// www.ema.europa.eu/en/human-regulatory/ research-development/compliance/goodmanufacturing-practice/mutual-recognitionagreements-mra#united-states-section 33. Bunnik EM, Aarts N, van de Vathorst S. The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications. J Pharm Policy Pract. 2017;10(1):10. doi:10.1186/ s40545-017-0100-3 34. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-World Evidence — What Is It and What Can It Tell Us? N Engl J Med. 2016;375(23):22932297. doi:10.1056/NEJMsb1609216 35. Hyry HI, Manuel J, Cox TM, Roos JCP. Compassionate use of orphan drugs. Orphanet J Rare Dis. 2015;10(1):100. doi:10.1186/s13023015-0306-x 36. Joffe S, Lynch HF. Federal Right-to-Try Legislation — Threatening the FDA’s Public Health Mission. N Engl J Med. 2018;378(8):695697. doi:10.1056/NEJMp1714054 37. Bateman-House A, Robertson CT. The Federal Right to Try Act of 2017—A Wrong Turn for Access to Investigational Drugs and the Path Forward. JAMA Intern Med. 2018;178(3):321. doi:10.1001/jamainternmed.2017.8167 38. Jacob JA. Questions of Safety and Fairness Raised as Right-to-Try Movement Gains Steam. JAMA. 2015;314(8):758-760. doi:10.1001/ jama.2015.7691 39. Folkers KM, Bateman-House A. Improving Expanded Access in the United States. Ther Innov Regul Sci. 2018;52(3):285-293. doi:10.1177/2168479018759661 40. Jarow JP, Moscicki R. Impact of Expanded Access on FDA Regulatory Action and Product Labeling. Ther Innov Regul Sci. 2017;51(6):787-789. doi:10.1177/2168479017707800 41. Puthumana J, Miller JE, Kim J, Ross JS.Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use Programs. JAMA Netw Open. 2018;1(2):e180283. doi:10.1001/ jamanetworkopen.2018.0283
RkJQdWJsaXNoZXIy MTk4NDMw